Funds and ETFs MorphoSys AG

Equities

MOR

DE0006632003

Biotechnology & Medical Research

Real-time Estimate Tradegate 07:32:52 2024-05-28 EDT 5-day change 1st Jan Change
67.92 EUR -0.26% Intraday chart for MorphoSys AG -0.80% +99.71%
MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
68.1 EUR
Average target price
58.71 EUR
Spread / Average Target
-13.78%
Consensus
  1. Stock Market
  2. Equities
  3. MOR Stock
  4. Funds and ETFs MorphoSys AG